Han Li, Xie Xiaoxiao, Zhuang Min, Wang Lu, Wu Xiaobo, Lu Man
Department of Ultrasound, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Department of Ultrasound, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
BMC Cancer. 2025 Apr 1;25(1):583. doi: 10.1186/s12885-025-13802-z.
To evaluate the efficacy and safety of ultrasound-guided percutaneous thermal ablation for abdominal wall metastases.
MATERIALS & METHODS: We retrospectively analyzed patients with abdominal wall metastatic nodules who underwent ultrasound-guided microwave ablation (MWA) from August 2018 to September 2024. Tumor volume (V), volume reduction rate (VRR), pain scores, and University of Washington Quality of Life (Uw-QOL) scores were measured at one, three, and six months postoperative.
A total of twelve patients were included in the study (8 males and 4 females), with one male patient excluded due to incomplete follow-up data. The median patient age was 51.5 years (range: 37-75). All patients were successfully treated, with no local recurrence noted during follow-up. Tumor volume reduction rates were 45.4%, 76.9%, and 96% at one, three, and six months, respectively. By the end of the follow-up period, the average pain scores decreased significantly from 7.09 ± 0.70 to 2.18 ± 1.16 (p < 0.001). The quality of life of patients was significantly improved, and the Uw-Qol of score increased from 1148.63 ± 94.07 to 1269.54 ± 118.25 (p < 0.05). No patient appeared serious complications. The clinical symptoms and quality of life of all patients were significantly improved.
Ultrasound-guided percutaneous thermal ablation is a safe and effective minimally invasive method for the treatment of metastatic nodules of abdominal wall, presenting a viable option for patients who are unsuitable for or unwilling to undergo surgery.
评估超声引导下经皮热消融治疗腹壁转移瘤的疗效和安全性。
我们回顾性分析了2018年8月至2024年9月期间接受超声引导下微波消融（MWA）治疗的腹壁转移瘤结节患者。在术后1个月、3个月和6个月测量肿瘤体积（V）、体积缩小率（VRR）、疼痛评分和华盛顿大学生活质量（Uw-QOL）评分。
本研究共纳入12例患者（8例男性，4例女性），其中1例男性患者因随访数据不完整被排除。患者中位年龄为51.5岁（范围：37-75岁）。所有患者均成功接受治疗，随访期间未发现局部复发。在1个月、3个月和6个月时，肿瘤体积缩小率分别为45.4%、76.9%和96%。到随访期末，平均疼痛评分从7.09±0.70显著降至2.18±1.16（p<0.001）。患者的生活质量显著改善，Uw-Qol评分从1148.63±94.07提高到1269.54±118.25（p<0.05）。无患者出现严重并发症。所有患者的临床症状和生活质量均显著改善。
超声引导下经皮热消融是一种安全有效的治疗腹壁转移瘤结节的微创方法，为不适合或不愿接受手术的患者提供了一种可行的选择。
